Julie Magat Selected Research

Lipids

2/2016	Mapping of global R1 and R2* values versus lipids R1 values as potential markers of hypoxia in human glial tumors: A feasibility study.
2/2016	Monitoring Combretastatin A4-induced tumor hypoxia and hemodynamic changes using endogenous MR contrast and DCE-MRI.
1/2015	Oxygen Mapping within Healthy and Acutely Infarcted Brain Tissue in Humans Using the NMR Relaxation of Lipids: A Proof-Of-Concept Translational Study.
11/2014	Qualification of a noninvasive magnetic resonance imaging biomarker to assess tumor oxygenation.
1/2013	Application of MOBILE (mapping of oxygen by imaging lipids relaxation enhancement) to study variations in tumor oxygenation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Julie Magat Research Topics

Disease

14	Neoplasms (Cancer) 04/2016 - 07/2010
3	Hypoxia (Hypoxemia) 01/2017 - 10/2012
2	Cicatrix (Scar) 01/2019 - 01/2019
1	Atherosclerotic Plaque (Atheroma) 03/2020
1	Myocardial Infarction 12/2018
1	Atrial Fibrillation 03/2017
1	Pulmonary Arterial Hypertension 01/2017
1	Necrosis 04/2016
1	Edema (Dropsy) 02/2016
1	Brain Neoplasms (Brain Tumor) 02/2016
1	Hypertrophy 01/2016
1	Heart Diseases (Heart Disease) 01/2016
1	Cardiomegaly (Heart Hypertrophy) 01/2016
1	Tachycardia (Tachyarrhythmias) 01/2016
1	Breast Neoplasms (Breast Cancer) 03/2015
1	Brain Ischemia (Cerebral Ischemia) 01/2015
1	Stroke (Strokes) 01/2015
1	Kidney Neoplasms (Kidney Cancer) 03/2014
1	Fibrosarcoma 05/2013
1	Acute Promyelocytic Leukemia 01/2012
1	Leukemia 01/2012
1	Hyperthyroidism 06/2011

Drug/Important Bio-Agent (IBA)

6	Oxygen (Dioxygen)IBA 02/2016 - 06/2011
5	LipidsIBA 02/2016 - 01/2013
3	Biomarkers (Surrogate Marker)IBA 04/2016 - 11/2014
3	Sorafenib (BAY 43-9006)FDA Link 04/2016 - 10/2012
3	carbogenIBA 11/2014 - 06/2011
2	Choline (Choline Chloride)IBA 04/2016 - 05/2013
2	fosbretabulin (combretastatin A4)IBA 02/2016 - 11/2014
2	LuciferasesIBA 03/2015 - 03/2014
1	MonocrotalineIBA 01/2017
1	N- (2- (4- bromocinnamylamino)ethyl)- 5- isoquinolinesulfonamide (h89)IBA 04/2016
1	Small Interfering RNA (siRNA)IBA 04/2016
1	Phosphorylcholine (Phosphocholine)IBA 04/2016
1	Antineoplastic Agents (Antineoplastics)IBA 04/2016
1	gemcitabine triphosphateIBA 01/2016
1	Gemcitabine FDA Link 01/2016
1	Adenosine Triphosphate (ATP)IBA 01/2016
1	CalciumIBA 01/2016
1	Cytotoxins (Cytolysins)IBA 01/2016
1	Drug CombinationsIBA 01/2016
1	FluorineIBA 01/2016
1	Isoproterenol (Isoprenaline)FDA LinkGeneric 01/2016
1	rhodamine BIBA 03/2015
1	ferric oxide (iron oxide)IBA 03/2015
1	AcidsIBA 01/2015
1	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 01/2015
1	Glutathione Transferase (Glutathione S-Transferase)IBA 01/2015
1	Protons (Proton)IBA 11/2014
1	alovudineIBA 05/2013
1	Mitogen-Activated Protein KinasesIBA 10/2012
1	NitroimidazolesIBA 10/2012
1	mirdametinibIBA 10/2012
1	fluoroazomycin arabinosideIBA 10/2012
1	A-factor (Streptomyces)IBA 10/2012
1	Dihydrotachysterol (AT 10)IBA 10/2012
1	Aligeron (AS 2)IBA 01/2012
1	Arsenic Trioxide (Trisenox)FDA Link 01/2012
1	Thyroxine (Levothyroxine)FDA LinkGeneric 06/2011
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 07/2010
1	S-nitrosocaptoprilIBA 07/2010

Therapy/Procedure

4	Therapeutics 04/2016 - 06/2011
3	Electrodes (Electrode) 01/2019 - 03/2017
3	Radiotherapy 05/2013 - 07/2010
2	Catheters 01/2019 - 03/2017
1	Stents 03/2020
1	Catheter Ablation 03/2017
1	Drug Therapy (Chemotherapy) 01/2016
1	Aftercare (After-Treatment) 05/2013